Business Context and Reporting Period
This Form 8-K was filed by Cytoclonal Pharmaceutics Inc. (now eXegenics Inc.) on October 24, 2001. The report details a corporate restructuring event effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate name change and ticker symbol update rather than financial performance.
Material Changes
- Corporate Name Change: Effective October 24, 2001, the Company changed its name from Cytoclonal Pharmaceutics Inc. to eXegenics Inc.
- Merger Mechanism: The name change was effected under Delaware law in connection with the merger of the Company's wholly owned subsidiary, eXegenics Inc., into the parent Company.
- Trading Symbol: The Company's Nasdaq National Market symbol was changed to "EXEG" effective October 24, 2001.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies. It references a Press Release (Exhibit 99.1) for further details on the transactions, but the text of that release is not included in the provided input.
Investor Verification Checklist
- Verify the new ticker symbol "EXEG" on the Nasdaq National Market.
- Confirm the legal name change to eXegenics Inc. in corporate registries.
- Review the attached Press Release (Exhibit 99.1) for strategic rationale behind the merger and rebranding.
- Check subsequent filings for any financial impact resulting from the merger of the subsidiary.